CARB-X FUNDS DEBIOPHARM

  15 May 2019

CARB-X is awarding Debiopharm International SA of Lausanne, Switzerland, up to $2.1 million in non-dilutive funding with the possibility of $1.6 million more if certain project milestones are met, to advance the development of a new class of antibiotics that inhibit bacterial fatty acid biosynthesis, an essential pathway in many drug-resistant bacterial species.  This new class of antibiotics is in development for the treatment of hospital-acquired pneumonia caused by the multidrug-resistant superbug Acinetobacter baumannii.

Further reading: CARB-X
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Global Ambassador Network

Welcome at the AMR Insights Ambassador Network!

The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).

More information and free-of-charge registration
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!